143.35
-1.11 (-0.77%)
| Penutupan Terdahulu | 144.46 |
| Buka | 142.00 |
| Jumlah Dagangan | 333,834 |
| Purata Dagangan (3B) | 164,944 |
| Modal Pasaran | 5,746,198,016 |
| Harga / Pendapatan (P/E Ke hadapan) | 227.27 |
| Harga / Buku (P/B) | 7.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Aug 2026 |
| EPS Cair (TTM) | -1.36 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.37% |
| Nisbah Semasa (MRQ) | 25.98 |
| Aliran Tunai Operasi (OCF TTM) | -29.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.42 M |
| Pulangan Atas Aset (ROA TTM) | -22.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.43% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Belite Bio, Inc | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.25 |
|
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 53.93% |
| % Dimiliki oleh Institusi | 0.75% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Darwin Global Management, Ltd. | 31 Mar 2026 | 3,057,412 |
| Eventide Asset Management, Llc | 31 Mar 2026 | 357,650 |
| Patient Square Capital Lp | 31 Mar 2026 | 116,684 |
| Duquesne Family Office Llc | 31 Mar 2026 | 106,100 |
| Mpm Bioimpact Llc | 31 Mar 2026 | 88,045 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |